StemExpress expands into clinical market

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of its Clinical Grade Non-Transfusable products to researchers and clinicians developing studies related to transplantation, cell therapy, regenerative medicine, investigational new drug development and medical devices in preclinical and clinical phases. These new Clinical Grade Non-Transfusable products support a smooth transition from laboratory prototype to commercial production.

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of its Clinical Grade Non-Transfusable products to researchers and clinicians developing studies related to transplantation, cell therapy, regenerative medicine, investigational new drug development and medical devices in preclinical and clinical phases. These new Clinical Grade Non-Transfusable products support a smooth transition from laboratory prototype to commercial production.

The new product line features Clinical Grade Non-Transfusable Bone Marrow, Leukopaks®, Mobilized Leukopaks,® and Primary Cells. Soon to follow will be Transfusable Grade Clinical products.

Currently, with intercontinental staff and four locations nationwide, StemExpress facilities follow and comply with strict CFR 1271 FDA guidelines regarding the production, processing, and management of tissue-based cellular products to ensure overall quality and compliance, which is paramount to the success of the researchers and clinicians StemExpress supports. Through IRB-approved collection processes and protocols and with an ISO certified cGMP compliant cell manufacturing facility, the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

fujirebio-square-logo

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours